menu

Unravel Global Clinical Complexities in Head and Neck Cancers: Identifying Approaches to Improve Outcomes with Manageable Toxici

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Unravel Global Clinical Complexities in Head and Neck Cancers: Identifying Approaches to Improve Outcomes with Manageable Toxicities

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Formulating individualized treatment plans for patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) is increasingly essential and increasingly complex. Newer regimens have become the standard of care because of their efficacy in overall survival and reduced toxicities. So how do we deploy them now that they’re in our treatment armamentarium?

    Join Drs. Joël Guigay and Kevin Harrington as they explore the role of IO as the standard of care in SCCHN and discuss the potential of taxanes to reduce dependence on fluorouracil-based chemotherapeutic regimens. Tune in to make sure you’re meeting the needs of your patients’ with SCCHN.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Joël Guigay, MD, PhD
    Professor of Medicine
    Centre Antoine-Lacassagne
    Université Côte d’Azur
    Nice, France

    Advisory Role: BMS, Merck SD, Merck Serono, Nanobiotix 

    Kevin J. Harrington, MD
    Head of the Division of Radiotherapy & Imaging
    The Institute of Cancer Research
    London, UK

    Honoraria: Merck Sharp and Dohme, Amgen, Merck Serono, AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Replimune, Oncolys BioPharma, Mersana
    Consulting Fees or Advisory Role: AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono, Merck Sharp and Dohme, Pfizer, Replimune
    Speakers' Bureau: Bristol-Myers Squibb, Merck Sharp and Dohme, and Merck Serono
    Research Funding: AstraZeneca, Boehringer Ingelheim, Merck Sharp and Dohme, and Replimune

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed, RN, OCN has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Formulate treatment approaches for patients with R/M SCCHN that provide good overall survival and reduce toxicity
    • Discuss the current and future importance of taxanes in combination with mAbs in the management of R/M SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and HCPs treating patients with head and neck cancer in Europe and China/Asia Pacific.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this podcast activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.
    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Formulating individualized treatment plans for patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) is increasingly essential and increasingly complex. Newer regimens have become the standard of care because of their efficacy in overall survival and reduced toxicities. So how do we deploy them now that they’re in our treatment armamentarium?

    Join Drs. Joël Guigay and Kevin Harrington as they explore the role of IO as the standard of care in SCCHN and discuss the potential of taxanes to reduce dependence on fluorouracil-based chemotherapeutic regimens. Tune in to make sure you’re meeting the needs of your patients’ with SCCHN.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Joël Guigay, MD, PhD
    Professor of Medicine
    Centre Antoine-Lacassagne
    Université Côte d’Azur
    Nice, France

    Advisory Role: BMS, Merck SD, Merck Serono, Nanobiotix 

    Kevin J. Harrington, MD
    Head of the Division of Radiotherapy & Imaging
    The Institute of Cancer Research
    London, UK

    Honoraria: Merck Sharp and Dohme, Amgen, Merck Serono, AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Replimune, Oncolys BioPharma, Mersana
    Consulting Fees or Advisory Role: AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono, Merck Sharp and Dohme, Pfizer, Replimune
    Speakers' Bureau: Bristol-Myers Squibb, Merck Sharp and Dohme, and Merck Serono
    Research Funding: AstraZeneca, Boehringer Ingelheim, Merck Sharp and Dohme, and Replimune

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed, RN, OCN has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Formulate treatment approaches for patients with R/M SCCHN that provide good overall survival and reduce toxicity
    • Discuss the current and future importance of taxanes in combination with mAbs in the management of R/M SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and HCPs treating patients with head and neck cancer in Europe and China/Asia Pacific.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this podcast activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.
    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule2 Oct 2022
Webpack App